Mix-and-Match PanOptix/Vivity
ApprovedSmall molecule
Mix-and-Match PanOptix/Vivity is one of 29 small molecule programs targeting Cataract. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Dexamethasone Phosphate
EEyegate Pharmaceuticals, Inc.
Phase 3
Mix-and-Match PanOptix/Vivity
BBerkeley Eye Center
Approved
Ripasudil
KKowa Research Institute, Inc.
Phase 3
Idose TR
GGlaukos Corporation
Phase 3
OCS-01
QQuan Dong Nguyen
Phase 3
Zolymbus
AbbViePreclinical
Neurontin
VViatris Specialty LLC
Preclinical
Kenalog
BBassett Healthcare
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBerkeley Eye Center